Skip to main content

Table 1 Demographic data and clinical characteristics

From: Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population

Variable

Total (N = 132)

OA-Treated (n = 39)

OA-Untreated (n = 93)

P Value

Age, yr, No (%)

 Median, Range

63(30–88)

62(38–81)

64(30–88)

 

 ≤ 65

84(63.6)

26(66.7)

58(62.4)

0.639

 > 65

48(36.4)

13(33.3)

35(37.6)

Gender, No (%)

 Female

35(26.5)

12(30.8)

23(24.8)

0.473

 Male

97(73.5)

27(69.2)

70(75.2)

Smoking, No (%)

 No

60(45.5)

21(53.8)

39(41.9)

0.210

 Yes

78(54.5)

18(46.2)

54(58.1)

ECOG PS, No (%)

 0

55(41.7)

20(51.3)

35(37.6)

 

 1

22(16.7)

6(15.4)

16(17.2)

0.293

 2

47(35.6)

10(25.6)

37(39.8)

 3

8(6.0)

3(7.7)

5(5.4)

 

Histology, No (%)

 Squamous

54(40.9)

16(41.0)

38(40.9)

0.208

 Adenocarcinoma

49(37.1)

11(28.2)

38(40.9)

 Small cell

29(22.0)

12(30.8)

17(18.2)

Neoplasm staging, No (%)

 III

9(6..8)

2(5.1)

7(7.5)

0.285

 IV

106(80.3)

33(84.7)

73(78.5)

 Recurrent

17(12.9)

4(10.2)

13(14.0)

Family History, No (%)

 Yes

20(15.2)

8(20.5)

12(12.9)

0.266

 No

112(84.8)

31(79.5)

81(87.1)

No..of treatment line. No (%)

 

 1

40(30.3)

7(17.9)

33(35.5)

0.293

 2

77(58.3)

28(71.8)

49(52.7)

 3

12(9.1)

3(7.7)

9(9.7)

 4

3(2.3)

1(2.6)

2(2.2)

Recurrence after operation, No (%)

 Yes

17(12.9)

4(10.3)

13(14.0)

0.560

 No

115(87.1)

35(89.7)

80(86.0)

 Treatment regimen, No (%)

 ICIs monotherapy

26(19.7)

10(25.6)

16(17.2)

0.545

 ICIs + chemo

91(68.9)

26(66.7)

65(69.9)

 ICIs + anti-EGFR

2(1.5)

0(0.00)

2(2.2)

 ICIs + anti-angiogenesis

13(9.8)

3(7.7)

10(20.8)